Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.
2.

Zolpidem and Eszopiclone Pre-medication for PSG: Effects on Staging, Titration, and Adherence.

Holley AB, Londeree WA, Sheikh KL, Andrada TF, Powell TA, Khramtsov A, Hostler JM.

Mil Med. 2018 Jul 1;183(7-8):e251-e256. doi: 10.1093/milmed/usx038.

PMID:
29961838
3.

Sedative Hypnotics and the Risk of Falls and Fractures in the Elderly.

Andrade C.

J Clin Psychiatry. 2018 May/Jun;79(3). pii: 18f12340. doi: 10.4088/JCP.18f12340.

4.

Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis.

Kori S, Parmar A, Goyal J, Sharma S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 1;1074-1075:129-138. doi: 10.1016/j.jchromb.2018.01.005. Epub 2018 Jan 6.

PMID:
29396378
5.

Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis.

Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I.

Age Ageing. 2018 Mar 1;47(2):201-208. doi: 10.1093/ageing/afx167.

PMID:
29077902
6.
7.

Plasticity-Related Gene Expression During Eszopiclone-Induced Sleep.

Gerashchenko D, Pasumarthi RK, Kilduff TS.

Sleep. 2017 Jul 1;40(7). doi: 10.1093/sleep/zsx098.

8.

GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.

Berro LF, Andersen ML, Tufik S, Howell LL.

Neuropharmacology. 2017 Sep 1;123:299-309. doi: 10.1016/j.neuropharm.2017.05.010. Epub 2017 May 8.

9.

Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.

Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG.

Drug Saf. 2017 Jun;40(6):531-542. doi: 10.1007/s40264-017-0516-3.

PMID:
28247279
10.

Eszopiclone and Zolpidem Do Not Affect the Prevalence of the Low Arousal Threshold Phenotype.

Smith PR, Sheikh KL, Costan-Toth C, Forsthoefel D, Bridges E, Andrada TF, Holley AB.

J Clin Sleep Med. 2017 Jan 15;13(1):115-119. doi: 10.5664/jcsm.6402.

11.

New-Onset Visual Hallucinations With Eszopiclone.

McGuire JM, Duquette M, Burghart SM, Ferri MJ.

Prim Care Companion CNS Disord. 2016 Apr 14;18(2). doi: 10.4088/PCC.15l01859. eCollection 2016. No abstract available.

12.

Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury.

Tom SE, Wickwire EM, Park Y, Albrecht JS.

Sleep. 2016 May 1;39(5):1009-14. doi: 10.5665/sleep.5742.

13.

Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.

Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ.

Sleep. 2016 Mar 1;39(3):603-12. doi: 10.5665/sleep.5536.

14.

Eszopiclone versus zopiclone in the treatment of insomnia.

Pinto LR Jr, Bittencourt LR, Treptow EC, Braga LR, Tufik S.

Clinics (Sao Paulo). 2016 Jan;71(1):5-9. doi: 10.6061/clinics/2016(01)02.

15.

Drugs for Insomnia.

[No authors listed]

Med Lett Drugs Ther. 2015 Jul 6;57(1472):95-8. Review. No abstract available.

PMID:
26147892
16.

Zolpidem and eszopiclone prime α1β2γ2 GABAA receptors for longer duration of activity.

Dixon CL, Harrison NL, Lynch JW, Keramidas A.

Br J Pharmacol. 2015 Jul;172(14):3522-36. doi: 10.1111/bph.13142. Epub 2015 May 11.

Supplemental Content

Loading ...
Support Center